RxDoctor Payments Data

Rajinder Prasad, MD

Cardiovascular Disease · Lewes, DENPI 1417928565

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $44,465 of the $71,842 with a category attached, or 61.9%. 53 manufacturers reported payments, led by Boehringer Ingelheim at 58.5% of the total. Among cardiovascular disease clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$71,842in general payments, 2019–2025

Across 745 payments — averaging $96.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$42K
  • Medtronic$7K
  • Lilly USA, LLC$6K
  • Amgen$2K
  • Boston Scientific$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • plus $12K from 47 others

What the payments were for

  • Speaking & faculty fees$44,46562%
  • Travel & lodging$8581%
  • Food & beverage$26,42737%
  • Education$910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,842 in reported general payments places this provider in the 95th percentile of 104 cardiovascular disease providers in Delaware.

See all cardiovascular disease providers in Delaware

Medicare billing

Part B allowed, 2024
$1,697,841
Medicare patients
3,358
Services billed
16,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,023$1,270,533
XareltoRivaroxaban385$478,396
JardianceEmpagliflozin373$368,540
EntrestoSacubitril/Valsartan245$333,321
CamzyosMavacamten36$293,978
Repatha SureclickEvolocumab183$222,921
MultaqDronedarone Hcl24$50,744
FarxigaDapagliflozin Propanediol42$48,325
Repatha SyringeEvolocumab24$34,797
Praluent PenAlirocumab28$33,578
Metoprolol Succinate1,506$26,623
Ranolazine ErRanolazine237$25,609
Rosuvastatin Calcium854$20,450
VascepaIcosapent Ethyl22$20,093
Atorvastatin Calcium1,270$16,679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$975$1,270,5331,023 claims
Johnson & JohnsonXarelto$839$478,396385 claims
Boehringer IngelheimJardiance$42,054$368,540373 claims
NovartisEntresto$986$333,321245 claims
E.r. Squibb & Sons, L.L.C.Camzyos$1,391$293,97836 claims
AstraZenecaFarxiga, Brilinta$1,166$63,51954 claims
Sanofi-aventis U.S. LLCMultaq$128$50,74424 claims
Esperion Therapeutics, Inc.Nexlizet$246$16,19715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 cardiovascular disease providers in Delaware.

Other cardiovascular disease in Lewes

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →